
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
Mary Schmidt, MD, discusses challenges in translating infectious disease advice to policy action.
Segment Description: Mary Schmidt, MD, associate professor of Clinical Medicine at Virginia Commonwealth University, Inova Fairfax Campus, discusses challenges in translating infectious disease advice to policy action.






